Team:LZU-CHINA/Futurework

 cursor: pointer;
 cursor: -webkit-zoom-in;
 cursor: -moz-zoom-in;

} .zoom-img, .zoom-img-wrap {

 position: relative;
 z-index: 666;
 -webkit-transition: all 300ms;
 -o-transition: all 300ms;
 transition: all 300ms;

} img.zoom-img {

 cursor: pointer;
 cursor: -webkit-zoom-out;
 cursor: -moz-zoom-out;

} .zoom-overlay {

 z-index: 420;
 background: #fff;
 position: fixed;
 top: 0;
 left: 0;
 right: 0;
 bottom: 0;
 pointer-events: none;
 filter: "alpha(opacity=0)";
 opacity: 0;
 -webkit-transition: opacity 300ms;
 -o-transition: opacity 300ms;
 transition: opacity 300ms;

} .zoom-overlay-open .zoom-overlay {

 filter: "alpha(opacity=100)";
 opacity: 1;

} .zoom-overlay-open, .zoom-overlay-transitioning {

 cursor: default;

}

.mdc__toolbar--fixed{top: 16px;}

@font-face {font-family: 'Material Icons'; font-style: normal; font-weight: 400; src: local('Material Icons'), local('MaterialIcons-Regular'), url(https://static.igem.org/mediawiki/2017/d/d5/Lanzhou_wiki_MaterialIcons-Regular.woff) format('woff'); } .material-icons {font-family: 'Material Icons'; font-weight: normal; font-style: normal; font-size: 24px; line-height: 1; letter-spacing: normal; text-transform: none; display: inline-block; white-space: nowrap; word-wrap: normal; direction: ltr; -webkit-font-feature-settings: 'liga'; -webkit-font-smoothing: antialiased; }#home_logo, #sideMenu { display:none; } #sideMenu, #top_title, .patrollink  {display:none;} #content { width:100%; padding:0px;  margin-top:-7px; margin-left:0px;} body {background-color:white; margin: 0;} #bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; }#top_title{display:none; }#top_menu_under {position:relative; width:100%; height:18px } #top_menu_14 {position:fixed; width:100%; top:0px; left:0px; height:16px; background-color:#383838; border-bottom:2px solid black; z-index:9999 } #top_menu_inside {display:block; position:relative; width:960px; height:100%; margin:0px auto; padding:0 10px; border-left:1px solid #c8c8c8; border-right:1px solid #c8c8c8; font-family:'arial',sans-serif; font-size:12px; font-weight:400; color:#ffffff } #top_menu_inside ul {list-style:none; margin:0; padding:0 } #top_menu_inside li {float:left; padding:0px 25px 0px 20px; cursor:pointer; margin:0 } #top_menu_inside .has_submenu:hover {background-color:#000000; color:white; text-decoration:none } #top_menu_inside #user_item {float:right; padding-top:2px; margin-right:100px; cursor:pointer; color:orange } #top_menu_inside #user_item:hover {background-color:#000000; color:#ffc864 } #top_menu_inside #bars_item {position:absolute; top:1px; left:960px; z-index:2; cursor:pointer } #top_menu_inside #bars_box {position:absolute; right:0px; top:17px; min-height:100px; min-width:100px; color:black; background-color:white; border:1px solid black; box-shadow:rgba(50,50,50,0.75) 1px 1px 10px 0px; z-index:1 } #top_menu_inside .submenu {display:none; position:absolute; z-index:10; top:16px; left:20px; width:900px; min-height:80px; background-color:#000000; padding:10px 15px 20px 15px; box-shadow:rgba(10,10,10,0.75) 0px 5px 15px 0px; color:#ffffff } #top_menu_inside .section {float:left; width:190px; font-family:helvitica,sans-serif; font-style:normal; font-weight:400; font-size:14px; line-height:22px; text-align:justify } #top_menu_inside .section .google span {padding-left:20px } #top_menu_inside .section .google span:hover,#top_menu_inside .section #page_go:hover {text-decoration:none; color:orange } #top_menu_inside .h1 {font-style:normal; font-size:18px; line-height:24px; text-weight:600; text-decoration:underline; text-align:left } #top_menu_inside .intro {color:#ffffff; font-style:italic; font-weight:normal; font-size:16px } #top_menu_inside .has_submenu .intro a {color:#ffffff; cursor:pointer } #top_menu_inside .has_submenu .intro a:hover {color:orange }

.mdc-toolbar--fixed{top: 16px !important;}</style>

<a href="Home.html">Home</a>
<a class="dropdown-toggle" href="#" id="1" data-toggle="dropdown">Team</a>

<a class="dropdown-item" href="generic.html">Team</a> <a class="dropdown-item" href="elements.html">Attribution</a> <a class="dropdown-item" href="elements.html">collaborations</a>
<a class="dropdown-toggle" href="Project.html" id="2" data-toggle="dropdown">Project</a>

<a class="dropdown-item" href="Project.html">Description</a> <a class="dropdown-item" href="generic.html">Design</a> <a class="dropdown-item" href="elements.html">part</a> <a class="dropdown-item" href="generic.html">experiment</a> <a class="dropdown-item" href="Safety.html">safety</a>
<a class="dropdown-toggle" href="#" id="3" data-toggle="dropdown">wet lab</a>

<a class="dropdown-item" href="generic.html">result</a> <a class="dropdown-item" href="elements.html">future work</a> <a class="dropdown-item" href="elements.html">interlab</a> <a class="dropdown-item" href="elements.html">notebook</a>
<a href="#secvice">dry lab</a>
<a class="dropdown-toggle" href="#" id="4" data-toggle="dropdown">HP</a>

<a class="dropdown-item" href="generic.html">intergrated hp</a> <a class="dropdown-item" href="elements.html">public engagement</a>
<a href="#home">award</a>

</nav> </header>

Future Work

</section>

1.Test the effectiveness of 5HRE-miniCMV promoter.

We will first construct 5HRE-miniCMV promoter, and then construct 5HRE-miniCMV-EGFP lentiviral plasmid. Use CoCl2-6H2O at different concentrations to induce hypoxia condition of 293T cell lines, and EGFP expression will be observed under an inverted fluorescence microscope.

2.Test the anti-tumor activity of other miRNA besides mir-135b-3p.

We will construct stable cell lines to overexpress mir-942-5p and mir-769-5p in MKN-45 and SGC7901 cell lines. Flow cytometry, scratch assay and CCK8 assay was respectively used to verify the inhibitory effect of microRNAs on gastric cancer cells at the cellular biological level.

3.Test the effectiveness of BS-Biotin-On system.

We will constrcut BS-Biotin-On-EGFP plamid to verify the effectiveness of BS-Biotin-On system and then construct regulatory and response vectors to control the expression of downstream interest gene (mir-135b-3p).

4.Test the anti-tumor activity of other miRNA besides mir-135b-3p.

We will construct stable cell lines to overexpress mir-942-5p and mir-769-5p in MKN-45 and SGC7901 cell lines. Flow cytometry, scratch assay and CCK8 assay was respectively used to verify the inhibitory effect of microRNAs on gastric cancer cells at the cellular biological level.

5.Identify target genes of miRNA.

Using RNA-seq and dual luciferase reporter system to identify target genes of miRNA.

6.Test the effectiveness of ECOB-P
minCMV
and P
GAL1

We will constrcut ECOB-P

minCMV

and P<p style="font-size: 10px;display: inline;">GAL1

plamids to verify whether tetracycline and galactosethe can respectively induce the expression of downstream interest gene mir-942-5p and mir-769-5p.

7. Fuse all our modules in one plasmid

To explore the best concentration of inducers that have the most effective anti-tumor activity.

8.Replace 293T cells with TIL cells.

Excise TIL cells from patients’(gastric cancer) body and then repeat all our experiments at the level of TIL cells.

</section>

</section> <footer class="footer-area section-gap" style="position: relative;">

</footer>

</div> <script type="text/javascript" src="https://2018.igem.org/wiki/index.php?title=Template:LZU-CHINA/Javascript/jquery1&action=raw&ctype=text/javascript"></script> <script type="text/javascript">

           jQuery(document).ready(function($){
               $('.scroll_top').click(function(){$('html,body').animate({scrollTop: '0px'}, 800);});
           });

</script> </div>

Team:LZU-CHINA/Futurework

Contents

Future Work

1.Test the effectiveness of 5HRE-miniCMV promoter.

2.Test the anti-tumor activity of other miRNA besides mir-135b-3p.

3.Test the effectiveness of BS-Biotin-On system.

4.Test the anti-tumor activity of other miRNA besides mir-135b-3p.

5.Identify target genes of miRNA.

6.Test the effectiveness of ECOB-P
minCMV
and P
GAL1

7. Fuse all our modules in one plasmid

8.Replace 293T cells with TIL cells.

About Us

Team:LZU-CHINA/Futurework

Contents

Future Work

1.Test the effectiveness of 5HRE-miniCMV promoter.

2.Test the anti-tumor activity of other miRNA besides mir-135b-3p.

3.Test the effectiveness of BS-Biotin-On system.

4.Test the anti-tumor activity of other miRNA besides mir-135b-3p.

5.Identify target genes of miRNA.

6.Test the effectiveness of ECOB-PminCMV and PGAL1

7. Fuse all our modules in one plasmid

8.Replace 293T cells with TIL cells.

About Us

Contact Us

6.Test the effectiveness of ECOB-P
minCMV
and P
GAL1